Axel Hauschild
Christian-Albrechts-Universität zu Kiel(DE)University Hospital Schleswig-Holstein(DE)Universitäts Hautklinik Kiel(DE)Universitätsmedizin Göttingen(DE)University of Lübeck(DE)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, CAR-T cell therapy research, Nonmelanoma Skin Cancer Studies, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
- → Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
- → Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial(2012)2,954 cited
- → Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib(2014)2,622 cited
- → Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited
- → Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma(2017)1,459 cited